Clinical trial NCT05166265: Clinical Investigation Study of Safety and Performance of the Sentio System.
Official title: A Prospective, Multi-center, Single-arm, Clinical Investigation of the Safety and Performance of the Sentio System in Users With Mixed/Conductive Hearing Losses and Single Sided Deafness
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Hearing Loss, Conductive
Hearing Loss, Mixed
Hearing Loss, Unilateral
Keywords: Hearing Loss
Conductive
Mixed
Single-sided
Deafness
Lead sponsor: Oticon Medical
Sponsor class: INDUSTRY
First posted: 2021-12-21
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Prospective, open label, single-arm, multi-centre investigation, designed to follow clinical practice for Sentio bone conduction devices in 50 subjects, during 10 clinical visits, and 24 months follow-up.

Detailed description: The investigation is a 24-months multinational, multicentre, prospective, open label, single arm investigation on the Sentio system. The purpose of this investigation is to evaluate safety and performance three months after implantation of the new Sentio system. In addition, safety will be analysed six months after implantation, and long-term safety and performance will be evaluated over a 24-month follow-up period. The endpoints chosen, together with applicable measurements, are commonly used, both in the clinical setting as well as in bone anchored hearing research as shown in the scientific literature covering this area. That is, the primary objectives of this study is to demonstrate that the Sentio system improves hearing and speech recognition on the implanted ear. Secondary objectives includes investigation of hearing improvement, speech intelligibility, patient satisfaction, and quality of life. The study also aims to evaluate the safety profile of the Sentio system in terms of the occurrence of adverse events and serious adverse events related to the device.

Eligibility criteria: Inclusion Criteria:

1. Signed Informed Consent Form
2. Adult subjects (18 years or older)
3. Subjects with 3.1. conductive or mixed hearing losses with pure tone average (PTA) bone conduction (BC) threshold (measured at 0.5, 1, 2 and 3 kHz) of the indicated ear better than or equal to 45 dB HL.

   3.2. OR subjects who have a profound sensorineural hearing loss in one ear and normal hearing in the opposite ear (i.e. SSD). The pure tone average (PTA) air conduction (AC) threshold of the hearing ear should then be better than or equal to 20 dB HL (measured at 0.5, 1, 2 and 3 kHz) 3.3. OR subjects who are indicated for an air-conduction contralateral routing of signals (ACCROS) hearing aid, but who for some reason cannot or will not use an AC CROS.
4. Fluent in local language
5. Subjects who have the ability and are willing to follow investigational procedures/requirements, e.g. to complete quality of life scales.

Exclusion Criteria:

1. Inability to undergo general or local anesthesia
2. Prior implantation with percutaneous device or middle ear implant on the side to be implanted
3. Known medical conditions that contraindicate undergoing surgery as judged by the investigator
4. Untreated ongoing middle ear infection at the time of surgery
5. Known insufficient bone quality/quantity/depth or skull size (scull abnormalities) for implantation of a Sentio Ti Implant
6. Known or suspected contact allergy to silicone or other material used in the Sentio system.
7. Known condition that could jeopardize wound healing and skin condition e.g. uncontrolled diabetes over time as judged by the investigator.
8. Known skin or scalp conditions that may preclude attachment or interfere with the usage of the sound processor.
9. Known retro cochlear pathology and auditory processing disorders that may have an impact on the outcome of the investigation
10. Any other known condition that the investigator determines could interfere with compliance or investigation assessments.
11. Use of ototoxic drugs that could be harmful to the hearing, as judged by the investigator.
12. Subject that has received radiotherapy in the area of implantation or is planned for such radiotherapy or similar during the investigation period.
13. For bilateral asymmetric candidates, subject already treated with a bone-anchored hearing solution on the side with the best bone conduction thresholds
14. Known chronic or non-revisable vestibular or balance disorder
15. Known abnormally progressive hearing loss
16. For conductive and mixed losses: evidence that hearing loss is retro-cochlear or of central origin
17. Participation in another clinical investigation with pharmaceuticals and/or devices which might cause interference with investigation participation.
18. Use of active implantable or body worn device that for medical reasons cannot be removed or discontinued, such as implantable cardiac pacemakers, defibrillators, or neurostimulators.
19. Known need for frequent MRI investigations for follow-up of other diseases.
20. Any subject that according to the Declaration of Helsinki is deemed unsuitable for investigation enrolment.

Primary outcomes:
measure: Demonstrate that the Sentio system improves hearing on the implanted ear.
timeFrame: 3 months post-surgery
measure: Demonstrate that the Sentio system provides patients with improved speech recognition on the implanted ear.
timeFrame: 3 months post-surgery
Secondary outcomes:
measure: Thorough assessment of performance (functional gain, effective gain, speech recognition), satisfaction, usability, comfort and health-related quality of life.
timeFrame: 3-24 months post-surgery
Other outcomes:
measure: Evaluate the safety profile of the Sentio system in terms of the occurrence of adverse events and serious adverse events related to the device.
timeFrame: 3 months post-surgery
Locations:
city: Freiburg
country: Germany
facility: Universitätsklinikum Freiburg Universitätsklinik für Hals,- Nasen und Ohrenheilkunde
city: Hanover
country: Germany
facility: HNO-Klinik Medizinische Hochschule Hanover
city: Groningen
country: Netherlands
facility: ENT Department, University Medical Center Groningen
city: Nijmegen
country: Netherlands
facility: ENT department Radboud University Medical Center (Radboud UMC)
city: Birmingham
country: United Kingdom
facility: ENT - University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham
city: Cambridge
country: United Kingdom
facility: Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital
Study officials:
affiliation: ENT Department, University Medical Center Groningen
name: Myrthe Hol, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: ENT Department, Radboud University Medical Center
name: Emmanuel Mylanus, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: ENT - University Hospitals Birmingham NHS, Foundation Trust
name: Peter Monksfield, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital
name: James Tysome, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Universitätsklinikum Freiburg
name: Susan Arndt, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: HNO-Klinik Medizinische Hochschule Hannover
name: Thomas Lenartz, MD, PhD
role: STUDY_DIRECTOR
References: